A study investigating the effects of SIRT1 activators and inhibitors on CD44+/CD133+-enriched NSCLC cells reported that SIRT1 can deacetylate the tumor suppressor protein P53, thereby decreasing its activity (87). This evidence concerns the gene SIRT1 and non-small cell lung carcinoma.